Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 349

Results For "C"

9223 News Found

AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
News | December 26, 2023

AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion

Furthering cell therapy ambition across oncology and autoimmune diseases


Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results
Drug Approval | December 26, 2023

Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure


BioVaxys executes LoI for major Immunotherapeutics technology acquisition
News | December 26, 2023

BioVaxys executes LoI for major Immunotherapeutics technology acquisition

BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement


Astellas completes acquisition of Propella Therapeutics
News | December 26, 2023

Astellas completes acquisition of Propella Therapeutics

Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer


Eugia's East Windsor facility gets 10 observations from USFDA
Drug Approval | December 25, 2023

Eugia's East Windsor facility gets 10 observations from USFDA

The plant is yet to start commercial operations


Stelis Biopharma updates on receipt of consideration from Syngene
News | December 25, 2023

Stelis Biopharma updates on receipt of consideration from Syngene

Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023


Ind-Swift Laboratories receives award from World HRD Congress
News | December 25, 2023

Ind-Swift Laboratories receives award from World HRD Congress

World HRD Congress is a well-known international body of Management Studies


Lyndra Therapeutics raises US$101 million in Series E funding
News | December 25, 2023

Lyndra Therapeutics raises US$101 million in Series E funding

Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners


Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion
News | December 24, 2023

Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion

Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety


Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA
Drug Approval | December 23, 2023

Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA

This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023